AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24833780 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein + multimode exercise training (PRISE)
Number of subjects: 79
Study 24833780 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein + resistance training (P + RT)
Number of subjects: 79
Study 24833780 — intervention group
Group type: COMPARATOR
Intervention: Whey protein only (P)
Number of subjects: 79
Study 22800470 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea
Number of subjects: 65
Study 22800470 — intervention group
Group type: EXPERIMENTAL
Intervention: Black tea
Number of subjects: 65
Study 22800470 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated water
Number of subjects: 65
Study 22800470 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 20615853 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual Acupuncture (MA)
Number of subjects: 40
Study 20615853 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) 10 Hz
Number of subjects: 40
Study 20615853 — intervention group
Group type: COMPARATOR
Intervention: Electroacupuncture (EA) 2 Hz
Number of subjects: 40
Study 20615853 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 40
Study 17765272 — intervention group
Group type: EXPERIMENTAL
Intervention: Apomorphine (5 microg/kg sc)
Number of subjects: 20
Study 17765272 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 15953577 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Number of subjects: 35
Study 15953577 — intervention group
Group type: COMPARATOR
Intervention: Gatifloxacin
Number of subjects: 35
Study 12447861 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 51
Study 12447861 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 51
Study 10599601 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient geriatric assessment with an intervention to increase adherence
Number of subjects: 351
Study 10599601 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 351
Study 7592202 — intervention group
Group type: EXPERIMENTAL
Intervention: Lesser Mueller maneuver
Number of subjects: 16
Study 7592202 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater Mueller maneuver
Number of subjects: 16
Study 1850576 — intervention group
Group type: EXPERIMENTAL
Intervention: Barley foods
Number of subjects: 21
Study 1850576 — intervention group
Group type: COMPARATOR
Intervention: Wheat foods
Number of subjects: 21
Study 7197493 — intervention group
Group type: EXPERIMENTAL
Intervention: Isobaric 0.5% tetracaine spinal anesthesia
Number of subjects: 98
Study 7197493 — intervention group
Group type: COMPARATOR
Intervention: Hyperbaric 0.5% tetracaine spinal anesthesia
Number of subjects: 98
Study 7197493 — intervention group
Group type: EXPERIMENTAL
Intervention: Isobaric tetracaine with dextrose
Number of subjects: 98
Study 7197493 — intervention group
Group type: COMPARATOR
Intervention: Isobaric tetracaine without dextrose
Number of subjects: 98
Study 29696833 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg twice daily
Number of subjects: 0
Study 29696833 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg twice daily
Number of subjects: 0
Study 29696833 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg twice daily (in ORAL Standard)
Number of subjects: 0
Study 29696833 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg twice daily (in ORAL Standard)
Number of subjects: 0
Study 29696833 — intervention group
Group type: COMPARATOR
Intervention: Control group (MTX or adalimumab)
Number of subjects: 0
Study 29562206 — intervention group
Group type: EXPERIMENTAL
Intervention: Semipermeable membrane (Tegaderm™)
Number of subjects: 164
Study 29562206 — intervention group
Group type: COMPARATOR
Intervention: No membrane (Control)
Number of subjects: 164
Study 27029546 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 32
Study 27029546 — intervention group
Group type: COMPARATOR
Intervention: Systemic Therapy (ST)
Number of subjects: 32
Study 24363128 — intervention group
Group type: EXPERIMENTAL
Intervention: CyA MEPC 2-3 mg/kg BW once a day before breakfast
Number of subjects: 48
Study 24363128 — intervention group
Group type: COMPARATOR
Intervention: CyA MEPC 1.5 mg/kg BW twice a day before meals
Number of subjects: 48
Study 24363128 — intervention group
Group type: EXPERIMENTAL
Intervention: CyA MEPC 2-3 mg/kg BW once a day (C2 ≥600 ng/mL)
Number of subjects: 48
Study 24363128 — intervention group
Group type: COMPARATOR
Intervention: CyA MEPC 1.5 mg/kg BW twice a day (C2 ≥600 ng/mL)
Number of subjects: 48
Study 20886571 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose pregabalin/tolterodine ER (150 mg BID/4 mg QD)
Number of subjects: 519
Study 20886571 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin alone (150 mg BID)
Number of subjects: 519
Study 20886571 — intervention group
Group type: COMPARATOR
Intervention: Tolterodine ER alone (4 mg QD)
Number of subjects: 519
Study 20886571 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 519
Study 20886571 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose pregabalin/tolterodine ER (75 mg BID/2 mg QD)
Number of subjects: 519
Study 19723121 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg tonabersat
Number of subjects: 0
Study 19723121 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg tonabersat
Number of subjects: 0
Study 19723121 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg sumatriptan (positive control)
Number of subjects: 0
Study 19723121 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17368154 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (10 mg daily, 5 mg for children younger than 12 months) for mean 484.7 days
Number of subjects: 42546
Study 17368154 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42546
Study 15129941 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenoidectomy or adenotonsillectomy
Number of subjects: 35
Study 15129941 — intervention group
Group type: COMPARATOR
Intervention: Control group (children without nasal complaints)
Number of subjects: 35
Study 12013585 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysport 500 units
Number of subjects: 68
Study 12013585 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 12013585 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysport 500 units (open phase treatment)
Number of subjects: 68
Study 12013585 — intervention group
Group type: COMPARATOR
Intervention: Placebo (open phase treatment)
Number of subjects: 68
Study 9141920 — intervention group
Group type: EXPERIMENTAL
Intervention: tranexamic acid (100 mg/kg, followed by 10 mg.kg‐1.h‐1)
Number of subjects: 41
Study 9141920 — intervention group
Group type: COMPARATOR
Intervention: saline placebo
Number of subjects: 41
Study 9141920 — intervention group
Group type: EXPERIMENTAL
Intervention: tranexamic acid
Number of subjects: 41
Study 8201089 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemofiltration and/or haemodialysis (Group HD)
Number of subjects: 26
Study 8201089 — intervention group
Group type: COMPARATOR
Intervention: Fluid infusion alone (Group non-HD)
Number of subjects: 26
Study 3322955 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine 800 mg daily
Number of subjects: 131
Study 3322955 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 800 mg plus pirenzepine 100 mg daily
Number of subjects: 131
Study 29331706 — intervention group
Group type: EXPERIMENTAL
Intervention: CAU plus the Internet intervention Deprexis
Number of subjects: 509
Study 29331706 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (CAU)
Number of subjects: 509
Study 27173813 — intervention group
Group type: EXPERIMENTAL
Intervention: Sipjeondaebo-tang (3 g, 3 times a day for 4 weeks)
Number of subjects: 40
Study 27173813 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3 times a day for 4 weeks)
Number of subjects: 40
Study 24987061 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab (in combination with CAPOX)
Number of subjects: 105
Study 24987061 — intervention group
Group type: COMPARATOR
Intervention: CAPOX (without cetuximab)
Number of subjects: 105
Study 23342566 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.23% APF gel for 1 minute
Number of subjects: 15
Study 23342566 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.23% APF gel for 4 minutes
Number of subjects: 15
Study 23342566 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% TiF4 solution for 1 minute
Number of subjects: 15
Study 23342566 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 15
Study 20518267 — intervention group
Group type: EXPERIMENTAL
Intervention: Gynemesh Prolift anterior kit
Number of subjects: 35
Study 20518267 — intervention group
Group type: COMPARATOR
Intervention: Individualized size of Gynemesh
Number of subjects: 35
Study 20518267 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Gynemesh Prolift and individualized Gynemesh)
Number of subjects: 35
Study 18156640 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine, risperidone, and typical antipsychotics
Number of subjects: 443
Study 15902862 — intervention group
Group type: EXPERIMENTAL
Intervention: CPM from 0 degrees to 40 degrees, increased by 10 degrees per day
Number of subjects: 147
Study 15902862 — intervention group
Group type: EXPERIMENTAL
Intervention: CPM from 90 degrees to 50 degrees (early flexion), progressed into full extension over 3 days
Number of subjects: 147
Study 15902862 — intervention group
Group type: COMPARATOR
Intervention: No CPM (control group)
Number of subjects: 147
Study 12865605 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg of citicoline twice per day
Number of subjects: 30
Study 12865605 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 10225070 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic epidural analgesia (TEA) with buprenorphine 0.15 mg
Number of subjects: 40
Study 10225070 — intervention group
Group type: COMPARATOR
Intervention: Lumbar epidural analgesia (LEA) with buprenorphine 0.15 mg
Number of subjects: 40
Study 10225070 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (TEA and LEA)
Number of subjects: 40
Study 8724116 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 219
Study 8724116 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Number of subjects: 219
Study 8724116 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet + Exercise
Number of subjects: 219
Study 8724116 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 219
Study 1909239 — intervention group
Group type: EXPERIMENTAL
Intervention: Loreclezole (targeted plasma level of 1-2 mg/l)
Number of subjects: 62
Study 1909239 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 6346912 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic injury prevention program
Number of subjects: 180
Study 6346912 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 180
Study 30592368 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic calcium sulfate/hydroxyapatite (BCS/HA)
Number of subjects: 33
Study 30592368 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine derived xenograft (BDX)
Number of subjects: 33
Study 30592368 — intervention group
Group type: COMPARATOR
Intervention: No grafting (Control)
Number of subjects: 33
Study 28381307 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiplatelet drugs after ICH
Number of subjects: 633
Study 28381307 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group not specified)
Number of subjects: 633
Study 26875540 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg b.i.d.
Number of subjects: 99
Study 26875540 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg b.i.d.
Number of subjects: 99
Study 26875540 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib (both doses)
Number of subjects: 99
Study 26875540 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety assessment
Number of subjects: 99
Study 24107831 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine 5 mg/mL, 45 mL
Number of subjects: 69
Study 24107831 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine 7.5 mg/mL, 30 mL
Number of subjects: 69
Study 24107831 — intervention group
Group type: COMPARATOR
Intervention: Levobupivacaine 7.5 mg/mL mixed with 0.9% NaCl, 30 mL
Number of subjects: 69
Study 21705084 — intervention group
Group type: EXPERIMENTAL
Intervention: IOP adjusted for CCT using various correction formulae
Number of subjects: 1433
Study 21705084 — intervention group
Group type: COMPARATOR
Intervention: Original prediction model without IOP adjustment for CCT
Number of subjects: 1433
Study 21705084 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline IOP (adjusted for CCT or not)
Number of subjects: 1433
Study 21705084 — intervention group
Group type: EXPERIMENTAL
Intervention: CCT (with IOP adjusted for CCT)
Number of subjects: 1433
Study 19605409 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol 1.25 mg
Number of subjects: 1734
Study 17619914 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-steroidal anti-inflammatory drugs (NSAIDs)
Number of subjects: 0
Study 17619914 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulation
Number of subjects: 0
Study 17619914 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 0
Study 17619914 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 0
Study 17619914 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral therapy
Number of subjects: 0
Study 17619914 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise therapy
Number of subjects: 0
Study 17619914 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAIDs
Number of subjects: 0
Study 17619914 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electric nerve stimulation
Number of subjects: 0
Study 15094142 — intervention group
Group type: EXPERIMENTAL
Intervention: ACL reconstruction surgery using the bone‐patellar tendon‐bone technique
Number of subjects: 25
Study 11575416 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 1 mg kg(‐1) to a maximum of 25 mg
Number of subjects: 135
Study 11575416 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 100 microg kg(‐1) to a maximum of 4 mg
Number of subjects: 135
Study 11575416 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135
Study 9681663 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether
Number of subjects: 17
Study 9681663 — intervention group
Group type: COMPARATOR
Intervention: Sulfadoxine-pyrimethamine
Number of subjects: 17
Study 8121979 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided imagery group
Number of subjects: 30
Study 8121979 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation group
Number of subjects: 30
Study 8121979 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 8121979 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided imagery and relaxation groups
Number of subjects: 30
Study 8121979 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up investigation day in study 2
Number of subjects: 30
Study 2686409 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 750 mg twice daily for 14 days
Number of subjects: 22
Study 2686409 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin 500 mg four times a day for 14 days
Number of subjects: 22
Study 1067409 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial mouthrinse containing cetylpyridinium chloride and domiphen bromide
Number of subjects: 0
Study 1067409 — intervention group
Group type: COMPARATOR
Intervention: Control rinse (flavored water)
Number of subjects: 0
Study 28801309 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold-pressed turnip rapeseed oil (CPTRO) 35 mL for 6-8 weeks
Number of subjects: 37
Study 28801309 — intervention group
Group type: COMPARATOR
Intervention: Butter 37.5 g for 6-8 weeks
Number of subjects: 37
Study 28801309 — intervention group
Group type: EXPERIMENTAL
Intervention: CPTRO
Number of subjects: 37
Study 27421075 — intervention group
Group type: EXPERIMENTAL
Intervention: information + action control text messages
Number of subjects: 121
Study 27421075 — intervention group
Group type: COMPARATOR
Intervention: information only
Number of subjects: 121
Study 24398758 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed (500 mg/m² for 21 days)
Number of subjects: 0
Study 24398758 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel (75 mg/m² for 21 days)
Number of subjects: 0
Study 22540638 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief online intervention (routine practice)
Number of subjects: 15300
Study 22540638 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief assessment and feedback (routine practice)
Number of subjects: 15300
Study 22540638 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief assessment only
Number of subjects: 15300
Study 22540638 — intervention group
Group type: COMPARATOR
Intervention: No contact control group
Number of subjects: 15300
Study 20178093 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis extract (20 mg THC)
Number of subjects: 16
Study 20178093 — intervention group
Group type: COMPARATOR
Intervention: Diazepam (5 mg)
Number of subjects: 16
Study 18289159 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment with anthelmintic drugs
Number of subjects: 0
Study 18289159 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated or placebo)
Number of subjects: 0
Study 16816758 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-minute psycho-educational video
Number of subjects: 126
Study 16816758 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 126
Study 14639535 — intervention group
Group type: EXPERIMENTAL
Intervention: Emtricitabine (FTC) 200 mg once daily
Number of subjects: 82
Study 14639535 — intervention group
Group type: EXPERIMENTAL
Intervention: Emtricitabine (FTC) 25 mg once daily
Number of subjects: 82
Study 14639535 — intervention group
Group type: EXPERIMENTAL
Intervention: Emtricitabine (FTC) 100 mg once daily
Number of subjects: 82
Study 14639535 — intervention group
Group type: COMPARATOR
Intervention: Lamivudine (3TC) 150 mg 2 times/day
Number of subjects: 82
Study 10826333 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 86
Study 10826333 — intervention group
Group type: COMPARATOR
Intervention: Geritamine
Number of subjects: 86
Study 8963946 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 6
Study 8963946 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 6
Study 8963946 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 1984101 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone
Number of subjects: 6
Study 1984101 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 1984101 — intervention group
Group type: COMPARATOR
Intervention: Trimipramine
Number of subjects: 6
Study 6230892 — intervention group
Group type: EXPERIMENTAL
Intervention: Zimeldine
Number of subjects: 40
Study 6230892 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 31470260 — intervention group
Group type: EXPERIMENTAL
Intervention: Low FODMAP diet (LFD)
Number of subjects: 55
Study 31470260 — intervention group
Group type: COMPARATOR
Intervention: Standard diet (SD)
Number of subjects: 55
Study 29902217 — intervention group
Group type: EXPERIMENTAL
Intervention: Female + male group intervention arm
Number of subjects: 2670
Study 29902217 — intervention group
Group type: EXPERIMENTAL
Intervention: Female only group intervention arm
Number of subjects: 2670
Study 29902217 — intervention group
Group type: COMPARATOR
Intervention: Control group (no groups)
Number of subjects: 2670
Study 29902217 — intervention group
Group type: EXPERIMENTAL
Intervention: Female group intervention arm
Number of subjects: 2670
Study 27211522 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous oxycodone 20 mg
Number of subjects: 33
Study 27211522 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous oxycodone 20 mg plus naltrexone 2.4 mg (simulated crushed ALO-02)
Number of subjects: 33
Study 27211522 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% sodium chloride for injection)
Number of subjects: 33
Study 24776325 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training program (16 weeks, 50%-60% Vo2peak, 3 times per week)
Number of subjects: 46
Study 24776325 — intervention group
Group type: COMPARATOR
Intervention: Control group (sedentary)
Number of subjects: 46
Study 24776325 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training program
Number of subjects: 46
Study 23594808 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional polyethylene (group A)
Number of subjects: 28
Study 23594808 — intervention group
Group type: COMPARATOR
Intervention: Highly crosslinked polyethylene (group B)
Number of subjects: 28
Study 20170502 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (health promotion curriculum and policies in troop meetings)
Number of subjects: 76
Study 20170502 — intervention group
Group type: COMPARATOR
Intervention: Control (standard-care)
Number of subjects: 76
Study 17414980 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac (30 mg intraoperative dose)
Number of subjects: 89
Study 17414980 — intervention group
Group type: COMPARATOR
Intervention: Control (no Ketorolac)
Number of subjects: 89
Study 17414980 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 89
Study 16298922 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Education Programme 'Discovering New Ways'
Number of subjects: 229
Study 16298922 — intervention group
Group type: COMPARATOR
Intervention: Individual Programme
Number of subjects: 229
Study 11865837 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PXF) 400 mg three times daily
Number of subjects: 85
Study 11865837 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study 10219067 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 34
Study 10219067 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 34